SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders
VERVNEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
VERVBALA CYNWYD, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders
VERVNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones. Halper Sadeh encourag
Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
VERVMILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Verve will receive $10.50 per share in cash (an aggregate of approximately $1.
Verve Therapeutics Q1 EPS $(0.35) Versus $(0.59) YoY, Sales $32.98M
VERVCantor Fitzgerald Upgrades Verve Therapeutics to Overweight
VERVGuggenheim Maintains Buy on Verve Therapeutics, Raises Price Target to $24
VERVCanaccord Genuity Maintains Buy on Verve Therapeutics, Raises Price Target to $39
VERVAssessing Verve Therapeutics: Insights From 4 Financial Analysts
VERVHC Wainwright & Co. Maintains Buy on Verve Therapeutics, Raises Price Target to $25
VERVVerve Therapeutics Reports Results for Heart-2 Trial, Achieving 69% LDL-C Reduction with VERVE-102
VERVVerve Therapeutics Receives FDA Fast Track Designation For Its VERVE-102 In Vivo Base Editing Medicine Targeting PCSK9
VERVGuggenheim Reiterates Buy on Verve Therapeuticsto Buy
VERVHC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
VERVVerve Therapeutics Reports Clearance Of IND Application By FDA For VERVE-102 For Treatment Of Patients Living With Heterozygous Familial Hypercholesterolemia And/Or Premature Coronary Artery Disease
VERVRBC Capital Maintains Outperform on Verve Therapeutics, Lowers Price Target to $15
VERVHC Wainwright & Co. Maintains Buy on Verve Therapeutics, Raises Price Target to $15
VERVVerve Therapeutics Advances Heart-2 Trial, Expects Key 2025 Milestones In Cardiovascular Gene Therapy
VERVVerve Therapeutics Says Well-capitalized With Cash Runway Extending Into Mid-2027
VERVRBC Capital Maintains Outperform on Verve Therapeutics, Lowers Price Target to $17
VERVAnalyst Scoreboard: 4 Ratings For Verve Therapeutics
VERVHC Wainwright & Co. Maintains Buy on Verve Therapeutics, Lowers Price Target to $14
VERVVerve Therapeutics Ended Q3 2024 With Cash, Cash Equivalents, And Marketable Securities Of $539.9M With Cash Runway Through 2026
VERVVerve Therapeutics Q3 2024 GAAP EPS $(0.59) Beats $(0.69) Estimate, Sales $6.87M Beat $2.81M Estimate
VERV